colchicine in heart failure

Phase 3

Recruiting

• Conditions: Ischemic and non-ischemic heart failure with reduced ejection fraction (less than 40%).; Heart failure

• Registration Number: IRCT20240617062161N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

chronic heart failure with reduced left ventricular ejection fraction(40%>)
The diagnosis of heart failure with reduced ejection fraction has been confirmed at least one year ago
At least for 3 months under standard medical treatment
Stable and compensated clinical conditions

Exclusion Criteria

Acute cardiac ischemic event within a year before or during the study
Getting cancer
Not taking regular medications in the previous 3 months
Acute myocarditis
Acute pericarditis
Suffering from other chronic inflammatory diseases such as vascular collagen diseases or infectious diseases
Heart surgery in the last 6 months
Cerebral vascular events during the last 6 months
Patients who need colchicine due to other diseases (such as gout)
History of colchicine intolerance

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hs-CRP plasma level. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: kit test.

Secondary Outcome Measures

Name	Time	Method
Interleukin 6 plasma level. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: kit test.;Pro-BNP plasma level. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Kit test.;NHA functional class. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: NHA functional class questionnaire.;6MWT. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Measuring tape.